Cutaneous lymphoma after organ transplantation is rare and its diagnosis may be delayed by both atypical clinical manifestations and failure to consider it in the differential diagnosis. Beside skin-directed therapy for the stage, immunosuppression reduction is also important for disease control.
A 50 years-old Caucasian man was referred to our outpatient clinic with a two months history of mildly pruritic red-brown patches on his lower limbs (figure 1).
He had had a kidney transplant seven years before, with unknown cause of renal failure and was medicated with tacrolimus 2 mg bid, prednisolone 5 mg and mychophenolate mofetil 500 mg bid. In our patient, the atypical presentation mimicking pigmented purpuric dermatosis also delayed the diagnosis.
Immunosuppression reduction should therefore be the first option in the primary cutaneous T-cell lymphoma 3, 6 , as we did in our patient. Changing calcineurin inhibitors to mTOR inhibitors, as everolimus and sirolimus, could also be an option in these patients, as reported in an European study 2 , but clinical guidelines are lacking.
Skin directed therapies must be added 2, 6 , since immunosuppression reduction alone is not able to clear all lesions, and it should be one of those recommended for the disease stage, as the topical corticosteroid we prescribed to our patient. Phototherapy, one of most used therapies in mycosis fungoides, should nevertheless be avoided in organ transplant recipients, since it will add to the already increased risk of non melanoma skin cancer in these patients. 
